NASH and Systemic Complications From Basic to Clinical Research

• Altri autori: Shiri-Sverdlov, Ronit (Redattore), Baumgartner, Sabine (Redattore)
• Natura: Elettronico Capitolo di libro
• Lingua: inglese
• Pubblicazione: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Soggetti: Research & information: general; NAFLD; mouse models; multifactorial disease; translational value; non-alcoholic fatty liver disease; steatohepatitis; NASH; cognitive impairment; memory dysfunction; Alzheimer's disease; neurodegeneration; liver stiffness; liver steatosis; controlled attenuation parameter; transient elastography; MRI PDFF; MR spectroscopy; non-alcoholic steatohepatitis (NASH); tunneling nanotubes (TNTs); primary hepatocytes; organelle transfer; mesenchymal stromal cells; aminopyrine; microsomal; liver function; breath test; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; extracellular vesicles; magnesium (Mg2+); obesity; insulin resistance (IR); type 2 diabetes mellitus (T2DM); hypertension; cardiovascular diseases (CVD); non-alcoholic steatohepatitis; intestinal permeability; microbiota; probiotics; physical exercise; fecal microbiota transplantation; hepatocellular carcinoma; pathogenesis; extra-hepatic outcome; organ-on-a-chip; artificial intelligence; liver disease; GLP-1 agonist; SGLT-2 inhibitor; type 2 diabetes; innate immune system; adaptive immune system; metabolic syndrome; fatty liver; leptin; n/a
• Accesso online: DOAB: download the publication; DOAB: description of the publication

Nonalcoholic fatty liver disease (NAFLD) is known as the hepatic manifestation of the metabolic syndrome, and while most patients develop simple steatosis, up to one-third can develop nonalcoholic steatohepatitis (NASH). NASH is a chronic inflammatory condition of the liver that can further progress...